补体在肾小球肾炎中的作用——新型疗法是否已可常规应用?
本综述讨论补体系统在C3肾小球病、IgA肾病、膜性肾病、ANCA相关性血管炎和狼疮性肾炎等肾小球疾病中的致病作用,并总结针对补体活性的新型靶向疗法;部分疗法已获批或处于临床开发后期,文中讨论了靶向补体的潜在获益与挑战。
要点
- 补体系统在C3肾小球病、IgA肾病、膜性肾病、ANCA相关性血管炎和狼疮性肾炎中起关键致病作用。
- 多种靶向补体活性的新型疗法已获批或处于临床开发后期。
- 综述讨论靶向补体系统治疗肾小球疾病的潜在获益与挑战。
核心结论
- 补体系统在多种病因的肾小球疾病中起关键致病作用,靶向补体活性的新型疗法部分已获批或处于临床开发后期,其潜在获益与挑战在本文中讨论。
研究设计与样本
- 综述,总结补体在肾小球疾病中作用的认识及正在开发的新型靶向疗法。
主要发现
- 补体系统在C3肾小球病、IgA肾病、膜性肾病、ANCA相关性血管炎和狼疮性肾炎中起关键致病作用。
- 多种靶向补体活性的新型疗法已获批或处于临床开发后期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complement system plays a key pathogenic role in glomerular diseases with a diverse range of aetiologies, including C3 glomerulopathy, immunoglobulin A nephropathy, membranous nephropathy, ANCA-associated vasculitis and lupus nephritis. Several novel therapies targeting complement activity have recently been developed, which have now been approved or are in the late stages of clinical development. In this review, potential benefits and challenges of targeting the complement system in glomerular disease are discussed. We summarize current understanding of the role of complement, and the novel targeted therapies that are being developed for the treatment of glomerular disease.
引用
- Cheung CK, Dormer JP, Barratt J, et al. The role of complement in glomerulonephritis-are novel therapies ready for prime time? Nephrol Dial Transplant. 2023. PMID: 36307926. doi:10.1093/ndt/gfac296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。